We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UCB Epilepsy Drug Vimpat's Patent Validated by U.S. Court
Read MoreHide Full Article
UCB S.A.’s (UCBJF - Free Report) shares gained 6% after the company announced that the Delaware District Court has confirmed the validity of the company’s patent (U.S. patent RE38,551) for its epilepsy drug, Vimpat.
However, the decision is currently under seal and will be released following an order from the court.
We note that the patent for the drug is due to expire in 2022.
We remind investors that Vimpat is approved in the U.S., both as an adjunct therapy and monotherapy, for the treatment of partial onset seizures in people with epilepsy who are 17 years and older. The drug is also approved in the EU as an adjunct therapy in the treatment of partial onset seizures with or without secondary generalization in patients aged 16 years and older with epilepsy. A Marketing Authorisation Application for Vimpat, as monotherapy in the treatment of partial onset seizures, is currently under review in the EU.
Moreover, in Jul 2016, Vimpat was approved in Japan as adjunctive therapy in the treatment of partial onset seizures, with or without secondary generalization, in adults with epilepsy who have not obtained sufficient response to other anti-epileptic drugs.
In the first half of 2016, the drug generated sales of €379 million driven by strong demand in the epilepsy indication.
Epilepsy affects approximately 65 million people worldwide. Approximately 1 in every 26 individuals are expected to suffer from epilepsy in their lifetime.
Meanwhile, Vimpat is being evaluated as adjunct therapy in a phase III studies for the treatment of partial onset seizures in pediatric patients. Results from the study are expected in 2017.
Drugs currently approved to treat epilepsy include Tegretol, Depakote and Topamax.
UCB currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Geron Corporation (GERN - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Each of these stock sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
UCB Epilepsy Drug Vimpat's Patent Validated by U.S. Court
UCB S.A.’s (UCBJF - Free Report) shares gained 6% after the company announced that the Delaware District Court has confirmed the validity of the company’s patent (U.S. patent RE38,551) for its epilepsy drug, Vimpat.
However, the decision is currently under seal and will be released following an order from the court.
We note that the patent for the drug is due to expire in 2022.
UCB SA Price
UCB SA Price | UCB SA Quote
We remind investors that Vimpat is approved in the U.S., both as an adjunct therapy and monotherapy, for the treatment of partial onset seizures in people with epilepsy who are 17 years and older. The drug is also approved in the EU as an adjunct therapy in the treatment of partial onset seizures with or without secondary generalization in patients aged 16 years and older with epilepsy. A Marketing Authorisation Application for Vimpat, as monotherapy in the treatment of partial onset seizures, is currently under review in the EU.
Moreover, in Jul 2016, Vimpat was approved in Japan as adjunctive therapy in the treatment of partial onset seizures, with or without secondary generalization, in adults with epilepsy who have not obtained sufficient response to other anti-epileptic drugs.
In the first half of 2016, the drug generated sales of €379 million driven by strong demand in the epilepsy indication.
Epilepsy affects approximately 65 million people worldwide. Approximately 1 in every 26 individuals are expected to suffer from epilepsy in their lifetime.
Meanwhile, Vimpat is being evaluated as adjunct therapy in a phase III studies for the treatment of partial onset seizures in pediatric patients. Results from the study are expected in 2017.
Drugs currently approved to treat epilepsy include Tegretol, Depakote and Topamax.
UCB currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Geron Corporation (GERN - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Each of these stock sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>